Should you buy Harmony Biosciences Holdings, I (HRMY)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
How the engine reached this verdict
TrendMatrix's engine output for Harmony Biosciences Holdings, I (HRMY) is STRONG_BUY_WAIT with medium conviction, score 6.6/10 at $32.05. The C-path quality+growth combination cleared its gates — quality 7.8 and growth 8.3 — with 2.05 asymmetric R:R supporting the read.
BUY_NOW requires asymmetry R:R climbing above the 2.5 conviction threshold (currently 4.02); the verdict flips to HOLD if overall score deteriorates by ~0.7.
On the bull side: High-quality business; Attractive valuation; Strong growth profile. On the bear side: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet; Consecutive earnings misses (3). Active engine warnings: L3:NEWS_MOD=-1: STRONG_BUY_NOW → STRONG_BUY_WAIT.
The engine's suggested entry zone is $30.14, currently 6.3% above entry. Target $38.60, stop $28.26, asymmetric R:R 4.02. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.8% of portfolio at this asymmetry level (high-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates HRMY — 10-dimension breakdown →
Bull case
- ▸High-quality business
- ▸Attractive valuation
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Product: WAKIX (98.0%)
- ▸Concentration risk — Supplier: Bioprojet
- ▸Consecutive earnings misses (3)